2023
Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes
Frampton J, Kearney K, Abbott J, Kereiakes D, Di Mario C, Saito S, Cristea E, Riley R, Fajadet J, Shlofmitz R, Ali Z, Klein A, Price M, Hill J, Stone G, Lansky A. Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101069. PMID: 39129889, PMCID: PMC11307843, DOI: 10.1016/j.jscai.2023.101069.Peer-Reviewed Original ResearchIntravascular lithotripsyLesion failureIschemia-driven target lesion revascularizationMajor adverse cardiac event ratesAdverse cardiac event ratesDrug-eluting stent placementMajor adverse cardiac eventsSmaller reference vessel diameterTarget vessel myocardial infarctionCoronary intravascular lithotripsyAdverse cardiac eventsCardiac event ratePrimary end pointTarget lesion failureTarget lesion revascularizationVessel myocardial infarctionReference vessel diameterAdverse clinical eventsHigh procedural successSex-based outcomesSex-specific outcomesLesion revascularizationAngiographic outcomesCardiac eventsCardiac death
2012
Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years
Lansky AJ, Brar SS, Yaqub M, Sood P, Applegate RJ, Lazar D, Jankovic I, Hermiller JB, Koo K, Sudhir K, Stone GW. Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years. The American Journal Of Cardiology 2012, 110: 21-29. PMID: 22464212, DOI: 10.1016/j.amjcard.2012.02.040.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicCoronary AngiographyCoronary Artery DiseaseEverolimusFollow-Up StudiesHumansImmunosuppressive AgentsPaclitaxelProspective StudiesProsthesis DesignReproducibility of ResultsSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeConceptsPaclitaxel-eluting stentsID-TLRAngiographic groupClinical followMajor adverse cardiovascular event ratesAdverse cardiovascular event ratesDrug-eluting stent placementMajor adverse cardiovascular eventsBare metal stent implantationSPIRIT IIILandmark survival analysisSPIRIT III trialAdverse cardiovascular eventsSafety end pointCardiovascular event ratesIschemia-driven revascularizationMajor clinical outcomesPercutaneous coronary interventionDrug-eluting stentsRoutine AngiographicCardiovascular eventsCoronary revascularizationRevascularization ratesCoronary interventionIII trials
2010
Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
Lansky AJ, Yaqub M, Hermiller JB, Smith RS, Farhat N, Caputo R, Williams JE, Sanz M, Koo K, Sood P, Sudhir K, Stone GW. Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention 2010, 6 Suppl J: j44-52. PMID: 21930490, DOI: 10.4244/eijv6supja8.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeUnited StatesConceptsPeriprocedural myocardial infarctionSide branch occlusionBranch occlusionMyocardial infarctionStent placementDrug-eluting stent placementIndependent angiographic core laboratoryPaclitaxel-eluting stent placementLong-term adverse outcomesSPIRIT III trialPaclitaxel-eluting stentsAngiographic core laboratoryThree-year resultsLower ratesSide branchesEES armIII trialsMI ratesIndependent predictorsClinical outcomesAdverse outcomesProcedural angiogramsGrade 0Stent typeCore laboratory
2008
Effectiveness of Drug-Eluting Stent Implantation for Patients With Unprotected Left Main Coronary Artery Stenosis
Kim YH, Dangas GD, Solinas E, Aoki J, Parise H, Kimura M, Franklin-Bond T, Dasgupta NK, Kirtane AJ, Moussa I, Lansky AJ, Collins M, Stone GW, Leon MB, Moses JW, Mehran R. Effectiveness of Drug-Eluting Stent Implantation for Patients With Unprotected Left Main Coronary Artery Stenosis. The American Journal Of Cardiology 2008, 101: 801-806. PMID: 18328844, DOI: 10.1016/j.amjcard.2007.10.052.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlood Vessel Prosthesis ImplantationCoated Materials, BiocompatibleCoronary AngiographyCoronary StenosisElectrocardiographyFemaleFollow-Up StudiesHumansImmunosuppressive AgentsMaleMyocardial RevascularizationPaclitaxelProspective StudiesSirolimusStentsTreatment OutcomeTubulin ModulatorsUltrasonography, InterventionalConceptsHigh surgical riskMain coronary artery stenosisMajor adverse cardiac eventsUnprotected LMCA stenosisAdverse cardiac eventsCoronary artery stenosisSurgical riskLMCA stenosisCardiac eventsArtery stenosisStent thrombosisMyocardial infarctionBifurcation stenosisUnprotected left main coronary artery stenosisLeft main coronary artery stenosisDrug-eluting stent placementUrgent percutaneous coronary interventionQ-wave myocardial infarctionFeasible therapeutic alternativeOutcomes of patientsPercutaneous coronary interventionPaclitaxel-eluting stentsSingle-stent strategyUnfavorable clinical outcomeSirolimus-eluting stents